Merck releases early PD-1 melanoma data

Share this article:

Merck's Phase Ib pipeline melanoma drug lambrolizumab shows that 81% of advanced melanoma patients survived for one year, across all doses. The company announced the data at the Congress of the Society for Melanoma Research in Philadelphia Monday.

The early data is a toehold of sorts in a PD-1 competition: PMLive notes that BMS has the Phase III PD-1 contender nivolumab, and Roche and  AstraZeneca also have anti-PD-1 drugs in the mix.

The class is considered a potential force across several indications, including melanoma and non-small lung cancer.

Monday's data correlates closely with Merck's increased focus on a smaller portfolio which will include vaccines, oncology, diabetes and acute care.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.